621 related articles for article (PubMed ID: 33932560)
1. Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting.
Hernández Borrero LJ; El-Deiry WS
Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188556. PubMed ID: 33932560
[TBL] [Abstract][Full Text] [Related]
2. Effects of TP53 mutational status on gene expression patterns across 10 human cancer types.
Parikh N; Hilsenbeck S; Creighton CJ; Dayaram T; Shuck R; Shinbrot E; Xi L; Gibbs RA; Wheeler DA; Donehower LA
J Pathol; 2014 Apr; 232(5):522-33. PubMed ID: 24374933
[TBL] [Abstract][Full Text] [Related]
3. How mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance.
Stiewe T; Haran TE
Drug Resist Updat; 2018 May; 38():27-43. PubMed ID: 29857816
[TBL] [Abstract][Full Text] [Related]
4. New therapeutic strategies to treat human cancers expressing mutant p53 proteins.
Blandino G; Di Agostino S
J Exp Clin Cancer Res; 2018 Feb; 37(1):30. PubMed ID: 29448954
[TBL] [Abstract][Full Text] [Related]
5. Small molecule compounds targeting the p53 pathway: are we finally making progress?
Yu X; Narayanan S; Vazquez A; Carpizo DR
Apoptosis; 2014 Jul; 19(7):1055-68. PubMed ID: 24756955
[TBL] [Abstract][Full Text] [Related]
6. Chaperoning the guardian of the genome. The two-faced role of molecular chaperones in p53 tumor suppressor action.
Wawrzynow B; Zylicz A; Zylicz M
Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):161-174. PubMed ID: 29355591
[TBL] [Abstract][Full Text] [Related]
7. Intratumour heterogeneity of p53 expression; causes and consequences.
Xue Y; San Luis B; Lane DP
J Pathol; 2019 Nov; 249(3):274-285. PubMed ID: 31322742
[TBL] [Abstract][Full Text] [Related]
8. Tumor suppressor p53 and its gain-of-function mutants in cancer.
Liu J; Zhang C; Feng Z
Acta Biochim Biophys Sin (Shanghai); 2014 Mar; 46(3):170-9. PubMed ID: 24374774
[TBL] [Abstract][Full Text] [Related]
9. The role of p53 in cancer drug resistance and targeted chemotherapy.
Hientz K; Mohr A; Bhakta-Guha D; Efferth T
Oncotarget; 2017 Jan; 8(5):8921-8946. PubMed ID: 27888811
[TBL] [Abstract][Full Text] [Related]
10. A ruthenium(II)-curcumin compound modulates NRF2 expression balancing the cancer cell death/survival outcome according to p53 status.
Garufi A; Baldari S; Pettinari R; Gilardini Montani MS; D'Orazi V; Pistritto G; Crispini A; Giorno E; Toietta G; Marchetti F; Cirone M; D'Orazi G
J Exp Clin Cancer Res; 2020 Jun; 39(1):122. PubMed ID: 32605658
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological activation of p53 in cancer cells.
Athar M; Elmets CA; Kopelovich L
Curr Pharm Des; 2011; 17(6):631-9. PubMed ID: 21391904
[TBL] [Abstract][Full Text] [Related]
12. Mutant p53 in breast cancer: potential as a therapeutic target and biomarker.
Duffy MJ; Synnott NC; Crown J
Breast Cancer Res Treat; 2018 Jul; 170(2):213-219. PubMed ID: 29564741
[TBL] [Abstract][Full Text] [Related]
13. The p53 Pathway: Origins, Inactivation in Cancer, and Emerging Therapeutic Approaches.
Joerger AC; Fersht AR
Annu Rev Biochem; 2016 Jun; 85():375-404. PubMed ID: 27145840
[TBL] [Abstract][Full Text] [Related]
14. Mutant p53 in cancer: new functions and therapeutic opportunities.
Muller PA; Vousden KH
Cancer Cell; 2014 Mar; 25(3):304-17. PubMed ID: 24651012
[TBL] [Abstract][Full Text] [Related]
15. Targeting mutant p53 for efficient cancer therapy.
Bykov VJN; Eriksson SE; Bianchi J; Wiman KG
Nat Rev Cancer; 2018 Feb; 18(2):89-102. PubMed ID: 29242642
[TBL] [Abstract][Full Text] [Related]
16. Non-coding RNAs, guardians of the p53 galaxy.
Chen S; Thorne RF; Zhang XD; Wu M; Liu L
Semin Cancer Biol; 2021 Oct; 75():72-83. PubMed ID: 32927018
[TBL] [Abstract][Full Text] [Related]
17. Roles of TP53 in determining therapeutic sensitivity, growth, cellular senescence, invasion and metastasis.
McCubrey JA; Lertpiriyapong K; Fitzgerald TL; Martelli AM; Cocco L; Rakus D; Gizak A; Libra M; Cervello M; Montalto G; Yang LV; Abrams SL; Steelman LS
Adv Biol Regul; 2017 Jan; 63():32-48. PubMed ID: 27776972
[TBL] [Abstract][Full Text] [Related]
18. Friend or Foe: MicroRNAs in the p53 network.
Luo Z; Cui R; Tili E; Croce C
Cancer Lett; 2018 Apr; 419():96-102. PubMed ID: 29330109
[TBL] [Abstract][Full Text] [Related]
19. P53/microRNA-34-induced metabolic regulation: new opportunities in anticancer therapy.
Zhang DG; Zheng JN; Pei DS
Mol Cancer; 2014 May; 13():115. PubMed ID: 24884974
[TBL] [Abstract][Full Text] [Related]
20. The p53 miRNA interactome and its potential role in the cancer clinic.
Krell J; Frampton AE; Colombo T; Gall TM; De Giorgio A; Harding V; Stebbing J; Castellano L
Epigenomics; 2013 Aug; 5(4):417-28. PubMed ID: 23895654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
